Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion

British Journal of Haematology

Volumn 113, Issue 4, 2001, Pages 1051-1059

  Mariani, Sara ^a   Coscia, Marta ^a   Even, Jos ^b   Peola, Silvia ^a   Foglietta, Myriam ^a   Boccadoro, Mario ^a   Sbaiz, Luca ^c   Restagno, Gabriella ^c   Pileri, Alessandro ^a   Massaia, Massimo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b INSTITUT PASTEUR   (France)

^c Azienda Ospedaliera di Torino   (Italy)

Author keywords

Immunocompetence; Myeloma; Remission; T cell oligoclonality; TCR

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; T LYMPHOCYTE RECEPTOR;

ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DRUG MEGADOSE; FLOW CYTOMETRY; HUMAN; MINIMAL RESIDUAL DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOMA; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR DENSITY; STEM CELL;

BONE MARROW CELLS; CASE-CONTROL STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC MEMORY; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; RECEPTORS, ANTIGEN, T-CELL; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 0034945969     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02871.x     Document Type: Article

References (42)

1. T cell receptor clonal diversity following allogeneic marrow grafting
2. T-cell clonal expansion in patients with B-cell lymphoproliferative disorders
3. A direct estimate of the human αβ T cell receptor diversity
4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
5. Detection of minimal residual disease in multiple myeloma and acute leukaemia
6. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
7. Diagnosis, prognosis, and standard treatment of multiple myeloma
8. 3H]-thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma, and remission phase myeloma: A reliable indicator of patients not requiring therapy
9. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors
10. The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma
11. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting
12. Mitogens, superantigens, and nominal antigens elicit distinctive patterns of TCRB CDR3 diversity
13. A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting features, response to treatment, and survival
14. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma
15. Selecting and maintaining a diverse T-cell repertoire
16. Oligoclonal expansion of CD8+ CD57+ T cells with restricted T-cell receptor beta chain variability after bone marrow transplantation
17. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy
18. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status
19. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation
20. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: Clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden
21. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
22. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial
23. Predominant T cell receptor V gene usage in patients with abnormal clones of B cells
24. Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a study of the Eastern Cooperative Oncology Group (E9487)
25. Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia
26. Correction of abnormal T-cell receptor repertoire during interferon-α therapy in patients with hairy cell leukemia
27. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
28. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex
29. Dysregulated Fas and bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients
30. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses alter high-dose chemotherapy
31. Stable clonal expansion of T cells induced by bone marrow transplantation
32. Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia
33. Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patients
34. The sizes of the CDR3 hypervariable regions of the murine T cell receptor beta chains vary as a function of the recombined germ-line segments
35. T-cell repertoire diversity and clonal expansions in normal and clinical samples
36. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas
37. Idiotype vaccination using dendritic cells alter autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study
38. T-cell repertoire complexity alter allogeneic bone marrow transplantation
39. Expanded CD4+ and CD8+ T cell clones in elderly humans
40. Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patients
41. Use of synthetic oligonucleotides as hybridization probes: Isolation of cloned cDNA sequences for human beta 2-microglobulin
42. The extent of the human germline T-cell receptor V beta segment repertoire